目的　探讨宫颈癌组织MDR1 和GST -π基因的表达和临床意义。方法　应用RT -PCR方法检测了 2 0例宫颈癌组织耐药基因MDR1 和GST -π。结果　宫颈癌组织MDR1 、GST-π阳性表达率分别为 65% (1 3/2 0 )、75% (1 5/2 0 ) ,MDR1 和GST -π共表达率为 50 % (1 0 /2 0 ) ,二者均表达阴性 2例 (1 0 % )。两种耐药基因表达与肿瘤分化、临床分期均无关。结论　宫颈癌组织中亦存在较高的MDR1 和GST -π基因表达 ,而二者在其先天性耐药机制中均占有重要的作用 ,这对今后治疗具有一定的参考价值 Objective To investigate the expression and clinical significance of MDR1 and GST-π in cervical cancer. Methods RT-PCR was used to detect the resistance gene MDR1 and GST-π in 20 cervical cancer tissues. Results The positive rates of MDR1 and GST-π in cervical cancer tissues were 65% (1/32) and 75% (15/2 0), respectively. The positive rates of MDR1 and GST-π were 50% (10/2 0), both negative expression in 2 cases (10%). Two kinds of drug resistance gene expression and tumor differentiation, clinical stage have nothing to do. Conclusion There is also a high expression of MDR1 and GST-π in cervical cancer tissues, both of which play an important role in their mechanism of congenital resistance, which is of certain value for future treatment